Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company... Show more
A.I.dvisor indicates that over the last year, OLMA has been loosely correlated with ARVN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if OLMA jumps, then ARVN could also see price increases.
| Ticker / NAME | Correlation To OLMA | 1D Price Change % | ||
|---|---|---|---|---|
| OLMA | 100% | +1.27% | ||
| ARVN - OLMA | 46% Loosely correlated | -0.37% | ||
| TARA - OLMA | 40% Loosely correlated | +2.56% | ||
| SRRK - OLMA | 36% Loosely correlated | +4.94% | ||
| VNDA - OLMA | 33% Loosely correlated | -2.13% | ||
| LRMR - OLMA | 33% Poorly correlated | -0.16% | ||
More | ||||
Industry Biotechnology
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where OLMA declined for three days, in 270 of 302 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.
OLMA broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for OLMA entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OLMA's RSI Oscillator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on OLMA as a result. In 67 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for OLMA just turned positive on October 21, 2026. Looking at past instances where OLMA's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.
Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where OLMA advanced for three days, in 225 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.490) is normal, around the industry mean (3.596). P/E Ratio (-3.458) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. OLMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OLMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.